Neuromyelitis Optica Spectrum Disorders clinical trials at UCSF
1 in progress, 0 open to eligible people
Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
Sorry, in progress, not accepting new patients
The objective of this study is to evaluate the safety and efficacy of eculizumab in pediatric participants (aged 2 to < 18 years) with relapsing neuromyelitis optica spectrum disorder (NMOSD).
San Francisco, California and other locations
Our lead scientists for Neuromyelitis Optica Spectrum Disorders research studies include Emmanuelle Waubant.